CAS NO: | 1338225-97-0 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Doravirine (MK-1439) is a highly specificHIV-1nonnucleosidereverse transcriptaseinhibitor withIC50s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type andK103NandY181Creverse transcriptasemutants, respectively[1]. | ||||||||||||||||
IC50& Target | IC50: 4.5 nM (wild typereverse transcriptase); 5.5 nM (K103N reverse transcriptase); 6.1 nM (Y181C reverse transcriptase)[1] | ||||||||||||||||
体外研究 (In Vitro) | Selectivity and cytotoxicity studies confirmed that Doravirine is a highly specific nonnucleoside reverse transcriptase inhibitors with minimum off-target activities. In the presence of 50% normal human serum (NHS), Doravirine shows excellent potency in suppressing the replication of WT virus, with a 95% effective concentration (EC95) of 20 nM, as well as K103N, Y181C, and K103N/Y181C mutant viruses withEC9595 of 43, 27, and 55 nM, respectively. Doravirine exhibits similar antiviral activities against 10 different HIV-1 subtype viruses (a total of 93 viruses)[1]. | ||||||||||||||||
体内研究 (In Vivo) | Administration of 50 mg Doravirine with a high-fat meal is associated with slight elevations in AUC time zero to infinity and C24 h with no change in Cmax[2]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 425.75 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C17H11ClF3N5O3 | ||||||||||||||||
CAS 号 | 1338225-97-0 | ||||||||||||||||
中文名称 | 多拉维林 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL(234.88 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|